Statistical Analyses
The MTD/RP2D of the combination treatment was estimated based on the anticipated probability of DLTs in cycle 1 for patients in the dose-determining set, which consisted of all phase Ib patients who met specified minimum exposure criteria and had sufficient safety evaluations during cycle 1 or who discontinued earlier due to a DLT during cycle 1.Efficacy analyses included all patients who received any dose of binimetinib or panitumumab. An estimation approach was to be used to assess exploratory efficacy for patient subgroups The safety analysis set included all patients who received ≥1 dose of binimetinib or panitumumab and had ≥1 valid postbaseline safety assessment.